Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 12/20 | 0.36 |
| ▸ | PTGES | O14684 | 2/20 | 0.35 |
| ▸ | RORC | P51449 | 1/20 | 0.34 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.33 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.33 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.32 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.32 |
| ▸ | METAP2 | P50579 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9898822 | 0.79 | EPHX2 (0.37) | P2RX7PTGESEPHX2NR1H4 | |
| SCHEMBL671339 | 0.79 | DGAT1 (0.40) | P2RX7PTGESRORCEPHX2NR1H4 | |
| SCHEMBL671291 | 0.79 | PTGES (0.42) | P2RX7PTGESTRPA1METAP2 | |
| SCHEMBL9899593 | 0.77 | PTGES (0.36) | PTGESEPHX2NR1H4 | |
| SCHEMBL9899188 | 0.76 | HDAC6 (0.38) | PTGESEPHX2NR1H4 | |
| SCHEMBL10091430 | 0.76 | P2RX7 (0.36) | P2RX7PTGESRORCEPHX2NR1H4 | |
| SCHEMBL670934 | 0.74 | IDO1 (0.39) | PTGES | |
| SCHEMBL9905721 | 0.72 | METAP2 (0.36) | P2RX7PTGESRORCMETAP2 | |
| SCHEMBL1727329 | 0.70 | PTGES (0.44) | P2RX7PTGESEPHX2DGAT1TRPA1 | |
| SCHEMBL1725947 | 0.70 | PTGES (0.41) | P2RX7PTGESEPHX2DGAT1TRPA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2606036-B1 | 2-ANILINOBENZIMIDAZOLE-6-CARBOXAMIDES AS ANTI-INFLAMMATORY AGENTS | BOEHRINGER INGELHEIM INT (DE) | 2014-10-08 | — | — | EP | disclosed |
| US-8759537-B2 | 3H-imidazo [4, 5-C] pyridine-6-carboxamides as anti-inflammatory agents | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-06-24 | — | — | US | disclosed |
| US-8586604-B2 | Inhibitors of the microsomal prostaglandin E2 synthase-1 | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-11-19 | — | — | US | disclosed |
| EP-2606036-A1 | NEW COMPOUNDS | Boehringer Ingelheim International GmbH (DE) | 2013-06-26 | — | — | EP | disclosed |
| EP-2606046-A1 | 2-(ARYLAMINO)-3H-IMIDAZO[4,5-B]PYRIDINE-6-CARBOXAMIDE DERIVATIVES AND THEIR USE AS MPGES-1 INHIBITORS | Boehringer Ingelheim International GmbH (DE) | 2013-06-26 | — | — | EP | disclosed |
| US-20120214786-A1 | NEW COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-08-23 | — | — | US | disclosed |
| US-20120208839-A1 | NEW COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-08-16 | — | — | US | disclosed |
| WO-2012022793-A1 | NEW COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-02-23 | — | — | WO | disclosed |
| WO-2012022792-A1 | 2-(ARYLAMINO)-3H-IMIDAZO[4,5-B]PYRIDINE-6-CARBOXAMIDE DERIVATIVES AND THEIR USE AS MPGES-1 INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-02-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120214786-A1 | NEW COMPOUNDS | PTGER1, PTGS1, PTGES | P2RX7 123/4885PTGES 3/4885RORC 805/4885 |
| US-20120208839-A1 | NEW COMPOUNDS | PTGER1, PTGS1, PTGES | P2RX7 170/4885PTGES 3/4885RORC 891/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.